{
    "clinical_study": {
        "@rank": "46824", 
        "arm_group": {
            "arm_group_label": "R-CHOP", 
            "arm_group_type": "Experimental", 
            "description": "rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day"
        }, 
        "brief_summary": {
            "textblock": "The aim of this study is to optimize the number of cycles of R-CHOP in patients with diffuse\n      large B-cell lymphoma based on the interim results of PET/CT."
        }, 
        "brief_title": "Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Diffuse Large B-cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "detailed_description": {
            "textblock": "R-CHOP is the standard regimen for patients with diffuse large B-cell lymphoma (DLBCL).\n      However, the standard number of cycles is uncertain. Recently, interim PET/CT was found to\n      predict prognosis in DLBCL. The hypothesis of this study is to optimize the number of cycles\n      based on the interim results of PET/CT in order to avoid treatment exposure."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previously untreated diffuse large B-cell lymphoma\n\n          -  Age range 18-80 years old\n\n          -  Eastern Cooperative Oncology Group performance status 0-2\n\n          -  Life expectancy of more than 3 months\n\n          -  Adequate organ function\n\n        Exclusion Criteria:\n\n          -  Primary or secondary central nervous system involvement\n\n          -  Previous serious cardiac disease\n\n          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma\n             in-situ of uterine cervix\n\n          -  Pregnant or lactating women\n\n          -  Serious uncontrolled diseases and intercurrent infection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "196", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01804127", 
            "org_study_id": "LMTG 13-01"
        }, 
        "intervention": {
            "arm_group_label": "R-CHOP", 
            "description": "rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day", 
            "intervention_name": "R-CHOP", 
            "intervention_type": "Drug", 
            "other_name": "mabthera"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "DLBCL", 
            "R-CHOP", 
            "PET/CT"
        ], 
        "lastchanged_date": "March 2, 2013", 
        "location": {
            "contact": {
                "email": "pattrick_guo@msn.com", 
                "last_name": "Ye Guo, MS", 
                "phone": "+86 21 64175590", 
                "phone_ext": "8906"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Fudan University Cancer Hospital"
            }, 
            "investigator": {
                "last_name": "Ye Guo, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Interim PET/CT Guided Cycle Numbers of R-CHOP in Patients With Diffuse Large B-cell Lymphoma: a Exploratory Phase II Study Study", 
        "overall_contact": {
            "email": "pattrick_guo@msn.com", 
            "last_name": "Ye Guo, MD", 
            "phone": "+86 21 64175590", 
            "phone_ext": "8906"
        }, 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Ye Guo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "3-year progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01804127"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Ye Guo", 
            "investigator_title": "Dr.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "3-year overall survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}